Lannett does not expect study to significantly impact Digoxin sales Lannett commented on the utilization of Digoxin, following a recently published abstract in the Journal of the American College of Cardiology, which suggested a potential increased risk of mortality in patients with newly diagnosed atrial fibrillation. The abstract was based on data of the TREAT-AF study from the U.S. Department of Veterans Affairs healthcare system, the company said. "Digoxin has long been an important treatment option for cardiovascular disease,” said Arthur Bedrosian, CEO of Lannett. “As with most medications, we believe medical care providers will continue to prescribe Digoxin unless a more effective alternative medication is available. The company said it does not expect prescriptions of Digoxin to be significantly impacted by the findings of the JACC study. Digoxin currently represents less than 10 percent of the company’s net revenues." Bedrosian went on to say that the company has "implemented a comprehensive strategy to expand and diversify its product offering by developing products internally, forming strategic alliances and acquiring products complementary to its business."